15 in stock
Selank 10 mg is a tuftsin-derived heptapeptide attracting research interest for its potential influence on calmness, stress resilience, GABA-related neurotransmission, attention, memory and neuroimmune signalling.
Selank is a synthetic seven-amino-acid peptide with the sequence Thr–Lys–Pro–Arg–Pro–Gly–Pro, commonly abbreviated TKPRPGP. It was developed from tuftsin, a naturally occurring immune-regulatory peptide fragment, with a Pro–Gly–Pro tail added to improve biological stability.
This structure places Selank at the intersection of neuroscience and immunology. Researchers are examining how it may influence GABA-related neurotransmission, regulatory peptide metabolism, stress-response behaviour, neurotrophic signalling and cytokine balance.
Unlike a conventional sedative, Selank research is centred on modulation rather than broad suppression of nervous-system activity. Early human studies reported anxiety-related improvements together with mild nootropic or antiasthenic effects, creating interest in a calmer state that may preserve mental clarity.
Early comparative human studies reported meaningful improvement on anxiety scales, supporting continued research into adaptive stress-response pathways.
Gene-expression research suggests that Selank may influence the GABAergic system through complex regulatory effects rather than acting as a conventional direct GABA-receptor agonist.
Human and animal findings have encouraged study of attention, memory, mental clarity and fatigue, especially where stress interferes with cognitive performance.
| Pathway | Research observation | Potential significance |
|---|---|---|
| GABAergic signalling | Selank altered expression of numerous neurotransmission-related genes in rat frontal cortex, with a pattern partly resembling GABA exposure. | May help explain calm-promoting effects without assuming that Selank acts exactly like a benzodiazepine. |
| Enkephalin metabolism | Laboratory research found inhibition of enzymes that degrade enkephalins and other regulatory peptides. | Could prolong endogenous peptide signals involved in stress, pain and emotional regulation. |
| BDNF regulation | Animal studies reported time-dependent changes in hippocampal BDNF gene expression and protein content. | Supports investigation of memory, learning, neuroplasticity and stress adaptation. |
| Neuroimmune signalling | Preclinical work has found changes in inflammatory cytokines, including IL-1β, IL-6 and TNF-α, under stress-related conditions. | Connects Selank’s tuftsin origin with the two-way relationship between immune activity, stress and cognition. |
| Research area | Encouraging finding | Evidence level | Interpretation |
|---|---|---|---|
| Generalized anxiety and neurasthenia | A 62-participant study reported anxiety improvement similar to medazepam, with additional antiasthenic and psychostimulant observations. | Small comparative human study | Promising direct human evidence, but not a large multicentre confirmatory trial. |
| Phobic-anxiety and somatoform disorders | A 60-participant comparison with phenazepam reported pronounced anxiolytic and mild nootropic effects, improved quality of life and an effect lasting one week after the study course. | Small comparative human study | Encouraging durability and cognitive findings require independent replication. |
| Stress behaviour | Rodent studies reported reduced anxiety-like behaviour and favourable effects under chronic unpredictable stress. | Controlled animal research | Supports mechanism research but cannot establish a human outcome. |
| Memory and attention | Animal models found protection against stress- or ethanol-associated memory impairment and signs of cognitive stimulation. | Preclinical behavioural research | A positive signal for cognition, not proof of general memory enhancement in healthy humans. |
| Neurotransmission | Gene-expression studies identified broad effects involving GABA, dopamine, serotonin, receptor and ion-channel pathways. | Molecular and animal research | Suggests a multi-pathway regulatory action rather than a single simple target. |
Investigating how peptide signalling may reduce excessive stress reactivity while preserving normal awareness and function.
Studying attention, information processing and fatigue where anxiety or prolonged stress disrupts cognitive performance.
Examining BDNF and other gene-response pathways connected with learning, memory and adaptive neural change.
Exploring how tuftsin-derived biology and cytokine modulation may connect immune status with mood and cognition.
| Feature | Selank | Semax |
|---|---|---|
| Peptide origin | Synthetic tuftsin analogue | Synthetic ACTH(4–7)-derived analogue |
| Primary research emphasis | Calmness, stress response and emotional regulation | Cognition, neuroprotection and neurotrophic signalling |
| Highlighted mechanisms | GABAergic gene expression, enkephalin metabolism and immune signalling | BDNF, NGF, melanocortin-related and oxidative-stress pathways |
| Shared interest | Stress-cognition interaction and adaptive neural signalling | Stress-cognition interaction and adaptive neural signalling |
The two peptides are related by their Pro–Gly–Pro-containing structures but should not be treated as interchangeable. Selank 10 mg is usually positioned around calm and stress-response research, whereas Semax 10 mg places greater emphasis on cognitive and neuroprotective pathways.
Published Selank studies have most often examined intranasal research preparations, while some laboratory and animal studies have used other routes. Absorption, stability and exposure can differ substantially by formulation and route.
The literature includes study-specific amounts and schedules, but these belong to particular experimental preparations, populations and controlled protocols. They should not be copied onto a different research product.
The 10 mg designation describes the total laboratory quantity in this vial. It is not a dose, cycle length, nasal-spray formula, reconstitution method or administration instruction. Canada Biogenix does not provide a human-use protocol for Selank 10 mg.
Selank’s research profile is encouraging because it includes direct human observations as well as mechanistic laboratory work. The comparative studies reported favourable anxiety, cognition and quality-of-life findings, and the preclinical literature offers plausible GABAergic, neurotrophic and neuroimmune pathways.
However, the human studies were relatively small, several publications are older and available primarily in Russian-language journals, and independent large-scale replication remains limited. There are no modern international Phase 3 trials establishing efficacy, long-term safety or an approved clinical regimen.
Overall, Selank remains an investigational research compound without a broadly established international clinical regimen. Even so, the existing findings support continued positive scientific interest while keeping claims proportional to an early human and preclinical evidence base.
| Research product | Primary pathway | Research emphasis |
|---|---|---|
| Selank 10 mg | GABA, regulatory peptides and neuroimmune signalling | Calmness, stress resilience and cognition |
| Semax 10 mg | BDNF, NGF and neurotrophic pathways | Cognitive performance and neuroprotection |
| DSIP 15 mg | Sleep and stress-regulation pathways | Sleep architecture and stress adaptation |
| NAD+ 500 mg | Cellular redox and energy metabolism | Cellular energy and healthy-aging research |
Selank 10 mg is supplied for qualified laboratory research and analytical applications. It is not represented as an approved therapeutic product, and this page does not provide medical advice, a treatment recommendation or a human administration protocol.
